Catalyst
Slingshot members are tracking this event:
Alkermes (ALKS) Phase 4 Study Testing ARISTADA TM (Aripiprazole Lauroxil) on Subjects With Schizophrenia Expected to Conclude September 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ALKS |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 10, 2017
Occurred Source:
https://clinicaltrials.gov/archive/NCT02634320/2017_08_10/changes
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Schizophrenia, Phase 4
